{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-001162","form_type":"8-K","ticker":"RLMD","cik":"0001553643","company_name":"RELMADA THERAPEUTICS, INC.","filed_at":"2023-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.549427+00:00","generated_at":"2026-06-20T19:36:04.864333+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Relmada Therapeutics engages director Paul Kelly as special advisor at $32k/mo; Kelly loses independent director status","bullets":["Paul Kelly, a director, entered Advisory Agreement as Special Advisor to CEO effective Jan 1, 2023, with $32,000 monthly fee.","Kelly will no longer be considered independent director; he resigns from Audit and Compensation Committees.","Charles J. Casamento appointed Chairman of Compensation Committee effective Jan 1, 2023.","Agreement term of one year, renewable automatically; early termination with 30 days' notice."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-001162","json":"https://secwatch.observer/filing/0001213900-23-001162.json","markdown":"https://secwatch.observer/filing/0001213900-23-001162.md","text":"https://secwatch.observer/filing/0001213900-23-001162.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023001162/0001213900-23-001162-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023001162/ea171314-8k_relmada.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T19:36:04.864333+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}